Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 106

1.

Drugs and Scaffold That Inhibit Cytochrome P450 27A1 In Vitro and In Vivo.

Lam M, Mast N, Pikuleva IA.

Mol Pharmacol. 2018 Feb;93(2):101-108. doi: 10.1124/mol.117.110742. Epub 2017 Nov 30.

PMID:
29192124
2.

Transcriptional and post-translational changes in the brain of mice deficient in cholesterol removal mediated by cytochrome P450 46A1 (CYP46A1).

Mast N, Lin JB, Anderson KW, Bjorkhem I, Pikuleva IA.

PLoS One. 2017 Oct 26;12(10):e0187168. doi: 10.1371/journal.pone.0187168. eCollection 2017. Erratum in: PLoS One. 2018 Jan 5;13(1):e0191058.

3.

Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Mast N, Saadane A, Valencia-Olvera A, Constans J, Maxfield E, Arakawa H, Li Y, Landreth G, Pikuleva IA.

Neuropharmacology. 2017 Sep 1;123:465-476. doi: 10.1016/j.neuropharm.2017.06.026. Epub 2017 Jun 24.

PMID:
28655608
4.

In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds.

Mast N, Anderson KW, Johnson KM, Phan TTN, Guengerich FP, Pikuleva IA.

J Biol Chem. 2017 Aug 4;292(31):12934-12946. doi: 10.1074/jbc.M117.794909. Epub 2017 Jun 22.

PMID:
28642370
5.

Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.

Mast N, Anderson KW, Lin JB, Li Y, Turko IV, Tatsuoka C, Bjorkhem I, Pikuleva IA.

J Biol Chem. 2017 Mar 24;292(12):4913-4924. doi: 10.1074/jbc.M116.774760. Epub 2017 Feb 11.

6.

On the importance of albumin binding for the flux of 7α-hydroxy-3-oxo-4-cholestenoic acid in the brain.

Saeed AA, Edström E, Pikuleva I, Eggertsen G, Björkhem I.

J Lipid Res. 2017 Feb;58(2):455-459. doi: 10.1194/jlr.P073403. Epub 2016 Dec 12.

7.

Retinal Hypercholesterolemia Triggers Cholesterol Accumulation and Esterification in Photoreceptor Cells.

Saadane A, Mast N, Dao T, Ahmad B, Pikuleva IA.

J Biol Chem. 2016 Sep 23;291(39):20427-39. doi: 10.1074/jbc.M116.744656. Epub 2016 Aug 11.

8.

Mapping of the Allosteric Site in Cholesterol Hydroxylase CYP46A1 for Efavirenz, a Drug That Stimulates Enzyme Activity.

Anderson KW, Mast N, Hudgens JW, Lin JB, Turko IV, Pikuleva IA.

J Biol Chem. 2016 May 27;291(22):11876-86. doi: 10.1074/jbc.M116.723577. Epub 2016 Apr 7.

9.

Cholesterol in mouse retina originates primarily from in situ de novo biosynthesis.

Lin JB, Mast N, Bederman IR, Li Y, Brunengraber H, Björkhem I, Pikuleva IA.

J Lipid Res. 2016 Feb;57(2):258-64. doi: 10.1194/jlr.M064469. Epub 2015 Dec 2.

10.

Cholesterol hydroperoxides as substrates for cholesterol-metabolizing cytochrome P450 enzymes and alternative sources of 25-hydroxycholesterol and other oxysterols.

van Lier JE, Mast N, Pikuleva IA.

Angew Chem Int Ed Engl. 2015 Sep 14;54(38):11138-42. doi: 10.1002/anie.201505002. Epub 2015 Jul 29.

11.

Histone H3 Ser57 and Thr58 phosphorylation in the brain of 5XFAD mice.

Anderson KW, Mast N, Pikuleva IA, Turko IV.

FEBS Open Bio. 2015 Jun 25;5:550-6. doi: 10.1016/j.fob.2015.06.009. eCollection 2015.

12.

Marketed Drugs Can Inhibit Cytochrome P450 27A1, a Potential New Target for Breast Cancer Adjuvant Therapy.

Mast N, Lin JB, Pikuleva IA.

Mol Pharmacol. 2015 Sep;88(3):428-36. doi: 10.1124/mol.115.099598. Epub 2015 Jun 16.

13.

Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain.

Anderson KW, Chen J, Wang M, Mast N, Pikuleva IA, Turko IV.

PLoS One. 2015 May 11;10(5):e0126592. doi: 10.1371/journal.pone.0126592. eCollection 2015.

14.

Mass spectrometry detection of isolevuglandin adduction to specific protein residues.

Charvet CD, Pikuleva IA.

Methods Mol Biol. 2015;1208:285-98. doi: 10.1007/978-1-4939-1441-8_21.

15.

Pathways of cholesterol homeostasis in mouse retina responsive to dietary and pharmacologic treatments.

Zheng W, Mast N, Saadane A, Pikuleva IA.

J Lipid Res. 2015 Jan;56(1):81-97. doi: 10.1194/jlr.M053439. Epub 2014 Oct 7.

16.

Retinal and nonocular abnormalities in Cyp27a1(-/-)Cyp46a1(-/-) mice with dysfunctional metabolism of cholesterol.

Saadane A, Mast N, Charvet CD, Omarova S, Zheng W, Huang SS, Kern TS, Peachey NS, Pikuleva IA.

Am J Pathol. 2014 Sep;184(9):2403-19. doi: 10.1016/j.ajpath.2014.05.024. Epub 2014 Jul 25.

17.

Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain.

Saeed AA, Genové G, Li T, Lütjohann D, Olin M, Mast N, Pikuleva IA, Crick P, Wang Y, Griffiths W, Betsholtz C, Björkhem I.

J Biol Chem. 2014 Aug 22;289(34):23712-22. doi: 10.1074/jbc.M114.556159. Epub 2014 Jun 27.

18.

Cholesterol in the retina: the best is yet to come.

Pikuleva IA, Curcio CA.

Prog Retin Eye Res. 2014 Jul;41:64-89. doi: 10.1016/j.preteyeres.2014.03.002. Epub 2014 Apr 4. Review.

19.

Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice.

Mast N, Li Y, Linger M, Clark M, Wiseman J, Pikuleva IA.

J Biol Chem. 2014 Feb 7;289(6):3529-38. doi: 10.1074/jbc.M113.532846. Epub 2013 Dec 18.

20.

7α-hydroxy-3-oxo-4-cholestenoic acid in cerebrospinal fluid reflects the integrity of the blood-brain barrier.

Saeed A, Floris F, Andersson U, Pikuleva I, Lövgren-Sandblom A, Bjerke M, Paucar M, Wallin A, Svenningsson P, Björkhem I.

J Lipid Res. 2014 Feb;55(2):313-8. doi: 10.1194/jlr.P044982. Epub 2013 Dec 8.

Supplemental Content

Loading ...
Support Center